NASDAQ · Biotechnology

Nexentis Technologies Inc. (NXTS) Stock

$0.86 -2.98% NASDAQ: NXTS Healthcare

Valuation

MetricValue
Price$0.86
Market Cap$48530
P/E Ratio-0.07
P/B Ratio0.59
P/S Ratio-1.18
EPS (TTM)$-25.02
52-Week High$49.00
52-Week Low$0.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-161.01%
ROA-85.74%
ROCE-73.72%
Gross Margin2.67%
Operating Margin103.62%
Net Margin155.62%
Debt/Equity0.22
Current Ratio6.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-5.0M$-6.0M$-7.0M$-4.0M$-4.0M
Net Profit$-5.0M$-6.0M$-7.0M$-5.0M$-4.0M
EPS$-504.05$-401.97$-190.14$-31.09$-60.27
Op Margin-1036.8%-1449.4%-2771.5%-1928.1%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$8.0M$6.0M$7.0M$5.0M$20.0M
Total Liabilities$1.0M$1.0M$1.0M$1.0M$5.0M
Cash$7.0M$6.0M$4.0M$2.0M$4.0M
Borrowings$0$0$0$0$1.0M

Latest News

Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative GlobeNewswire · Jul 7, 2026 Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS) InvestorsHub · Jun 29, 2026 Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment GlobeNewswire · Jun 29, 2026 Top Midday Decliners MT Newswires · Jun 23, 2026 Top Premarket Decliners MT Newswires · Jun 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-5.0M$-3.0M$-3.0M$-4.0M
Investing Cash Flow$0$0$-2.0M$-2.0M$-3.0M
Financing Cash Flow$0$0$3.0M$3.0M$4.0M
Net Cash Flow$7.0M$-1.0M$-1.0M$-2.0M$2.0M
Free Cash Flow$-4.0M$-5.0M$-3.0M$-3.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.82
FCF Yield-5974.47%
Quick Ratio3.72
Interest Coverage-24.93
Return 1Y-95.41%
Return 3Y-99.75%
Return 5Y-99.98%

Ownership

Insiders Held21.17%
Institutions Held1.11%
Institutions Float Held1.40%
Institutional HolderSharesReport Date
Geode Capital Management, LLC7,1202026-03-31
Xtx Topco Ltd3,1092026-03-31
Yorkville Advisors Global, LP2,3442026-03-31
UBS Group AG1,8722026-03-31
Vanguard Fiduciary Trust Co9982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Nexentis Technologies Inc.

Nexentis Technologies Inc. is led by CEO David Palach, employs 5 people, headquartered in IL, publicly traded since 2026.

Nexentis Technologies Inc. (NXTS) stock trades at $0.86 with a market capitalization of $48530. The stock is valued at a price-to-earnings (P/E) ratio of -0.07, price-to-book of 0.59, price-to-sales of -1.18. Over the past 52 weeks the stock has ranged between $0.86 and $49.00, and currently trades 98.2% below its 52-week high.

On profitability, Nexentis Technologies Inc. generates a return on equity (ROE) of -161.01%, return on capital employed of -73.72%, an operating margin of 103.62%, a net profit margin of 155.62%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides